6-碘-1-甲基-1H-吲唑 | 1214899-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-碘-1-甲基-1H-吲唑
• 英文名称: 6-iodo-1-methyl-1H-indazole
• 英文别名: 6-iodo-1-methylindazole
• CAS: 1214899-83-8
• 化学式: C₈H₇IN₂
• 分子量: 258.061
• InChiKey: ZOBWRJCBLYMZHH-UHFFFAOYSA-N

物化性质

• 沸点：
  318.4±15.0 °C(Predicted)
• 密度：
  1.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-碘-1-甲基-1H-吲唑 在 lithium aluminium tetrahydride 、 二(氰基苯)二氯化钯 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.17h， 生成 (Z)-5-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(4-methoxyphenyl)-4-(1-methylindazol-6-yl)pent-4-en-1-ol
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists

  摘要：

  Estrogen-related receptor gamma (ERRγ) has recently been recognized as an attractive target for treating inflammation, cancer, and metabolic disorders. Herein, we discovered and demonstrated the in vitro pharmacology as well as the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of chemical entities that could act as highly selective inverse agonists for ERRγ. The results were comparable to those for GSK5182 (4), a leading ERRγ inverse agonist ligand. Briefly, the half-maximal inhibitory concentration (IC50) range of the synthesized compounds for ERRγ was 0.1-10 μM. Impressively, compound 24e exhibited potency comparable to 4 but was more selective for ERRγ over three other subtypes: ERRα, ERRβ, and estrogen receptor α. Furthermore, compound 24e exhibited a superior in vitro ADMET profile compared to the other compounds. Thus, the newly synthesized class of ERRγ inverse agonists could be lead candidates for developing clinical therapies for ERRγ-related disorders.

  DOI：

  10.1016/j.ejmech.2016.04.076
• 作为产物：
  描述：

  1-甲基-6-氨基-1H-吲唑 、 sodium nitrite 、 碘化钾 在 水 作用下， 以 盐酸 、 水 为溶剂， 反应 16.5h， 以to give 6-iodo-1-methyl-1H-indazole (0.8 g, 44% yield) as a solid的产率得到6-碘-1-甲基-1H-吲唑
  参考文献：
  名称：

  AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

  摘要：

  本文提供了公式（I）的杂环芳基化合物：其中R1和R2如本文所定义，包含有效量的杂环芳基化合物的组合物以及用于治疗或预防炎症性疾病或癌症以及通过抑制激酶或激酶途径可治疗或预防的疾病的方法，包括向需要的受体中施用有效量的杂环芳基化合物。

  公开号：

  US20130005707A1

文献信息

• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。
• Phenylethynyl-substituted heterocycles inhibit cyclin D1 and induce the expression of cyclin-dependent kinase inhibitor p21^Wif1/Cip1in colorectal cancer cells
  作者：Vitaliy M. Sviripa、Liliia M. Kril、Wen Zhang、Yanqi Xie、Przemyslaw Wyrebek、Larissa Ponomareva、Xifu Liu、Yaxia Yuan、Chang-Guo Zhan、David S. Watt、Chunming Liu

  DOI：10.1039/c7md00393e

  日期：——

  heterocycles including pyridines, indoles, 1H-indazoles, quinolines, and isoquinolines inhibited the proliferation of LS174T colon cancer cells in which the inhibition of cyclin D1 and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21Wif1/Cip1) served as readouts for antineoplastic activity at a cellular level. At a molecular level, these agents, particularly 4-((2,6-difluorophenyl)et

  氟苯基乙炔基取代的杂环具有N-甲基氨基或与N，N-二甲基氨基连接的杂环，包括吡啶，吲哚，1 H-吲唑，喹啉和异喹啉，可抑制LS174T结肠癌细胞的增殖，其中Cyclin的抑制作用D1和细胞周期蛋白依赖性激酶抑制剂-1（即p21 Wif1 / Cip1）的诱导用作细胞水平抗肿瘤活性的读数。在分子水平上，这些试剂，特别是4-（（2,6-二氟苯基）乙炔基）-N-甲基异喹啉-1-胺和4-（（2,6-二氟苯基）乙炔基）-N，N-二甲基异喹啉-1-胺结合并抑制蛋氨酸S-腺苷基转移酶2（MAT2A）的催化亚基。
• AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Beijing Adamadle Biotechnology Limited Liability Company

  公开号：EP3640248A1

  公开（公告）日：2020-04-22

  The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

  本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示： 该化合物是表皮生长因子受体（EGFR）激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、其制备方法和在制备抗肿瘤药物中的用途。
• AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2344494A1

  公开（公告）日：2011-07-20
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2766346B1

  公开（公告）日：2017-03-29